Annovis Bio Inc. announced it will initiate an open-label extension study in January 2026 to further evaluate the long-term safety and efficacy of buntanetap in patients with Parkinson disease. The study will provide continued access to buntanetap for participants from prior clinical trials while enabling extended monitoring of safety outcomes, sustained effects on motor and cognitive function, and the collection of biomarker data to support further evaluation of buntanetap's potential as a disease-modifying therapy for neurodegenerative disorders.
The extension study represents a critical next step in understanding buntanetap's long-term profile and its ability to modify disease progression in Parkinson's patients. By offering continued treatment to previous trial participants, researchers can gather valuable data on how the therapy performs over extended periods, which is essential for assessing its viability as a chronic treatment for neurodegenerative conditions. The collection of biomarker data will be particularly important for establishing objective measures of the drug's impact on disease pathology.
This development matters because Parkinson's disease affects millions worldwide, with current treatments primarily addressing symptoms rather than modifying the underlying disease progression. A successful disease-modifying therapy could represent a significant advancement in neurodegenerative care. The study's focus on both motor and cognitive function addresses two key areas of impairment in Parkinson's patients, suggesting a comprehensive approach to treatment evaluation.
The company's commitment to addressing neurodegeneration in diseases such as Alzheimer's and Parkinson's through innovative therapies that target multiple neurotoxic proteins positions this research within a broader context of neurodegenerative treatment development. The open-label extension study design allows for continued patient access while generating important long-term data that could support regulatory submissions and further clinical development. For more information about the company, visit https://www.AnnovisBio.com. Additional news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS. The original press release can be viewed at https://ibn.fm/MaSkN.
